全文获取类型
收费全文 | 516篇 |
免费 | 55篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 11篇 |
妇产科学 | 14篇 |
基础医学 | 105篇 |
口腔科学 | 16篇 |
临床医学 | 57篇 |
内科学 | 91篇 |
皮肤病学 | 8篇 |
神经病学 | 36篇 |
特种医学 | 7篇 |
外科学 | 47篇 |
预防医学 | 59篇 |
眼科学 | 24篇 |
药学 | 42篇 |
肿瘤学 | 48篇 |
出版年
2023年 | 7篇 |
2022年 | 2篇 |
2021年 | 6篇 |
2020年 | 11篇 |
2019年 | 12篇 |
2018年 | 11篇 |
2017年 | 14篇 |
2016年 | 15篇 |
2015年 | 15篇 |
2014年 | 20篇 |
2013年 | 19篇 |
2012年 | 39篇 |
2011年 | 42篇 |
2010年 | 11篇 |
2009年 | 20篇 |
2008年 | 26篇 |
2007年 | 26篇 |
2006年 | 39篇 |
2005年 | 46篇 |
2004年 | 45篇 |
2003年 | 38篇 |
2002年 | 39篇 |
2001年 | 4篇 |
2000年 | 3篇 |
1999年 | 3篇 |
1998年 | 10篇 |
1997年 | 8篇 |
1996年 | 6篇 |
1995年 | 9篇 |
1994年 | 4篇 |
1993年 | 6篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1985年 | 1篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有571条查询结果,搜索用时 15 毫秒
1.
Kirton CM Laukkanen ML Nieminen A Merinen M Stolen CM Armour K Smith DJ Salmi M Jalkanen S Clark MR 《European journal of immunology》2005,35(11):3119-3130
Human vascular adhesion protein-1 (VAP-1) is a homodimeric 170-kDa sialoglycoprotein that is expressed on the surface of endothelial cells and functions as a semicarbazide-sensitive amine oxidase and as an adhesion molecule. Blockade of VAP-1 has been shown to reduce leukocyte adhesion and transmigration in in vivo and in vitro models, suggesting that VAP-1 is a potential target for anti-inflammatory therapy. In this study we have constructed mouse-human chimeric antibodies by genetic engineering in order to circumvent the potential problems involved in using murine antibodies in man. Our chimeric anti-VAP-1 antibodies, which were designed to lack Fc-dependent effector functions, bound specifically to cell surface-expressed recombinant human VAP-1 and recognized VAP-1 in different cell types in tonsil. Furthermore, the chimeric antibodies prevented leukocyte adhesion and transmigration in vitro and in vivo. Hence, these chimeric antibodies have the potential to be used as a new anti-inflammatory therapy. 相似文献
2.
Mohammad A. Karim Koji Suzuki Kazuyoshi Fukai Jangsuk Oh Deborah L. Nagle Karen J. Moore Ernest Barbosa Tzipora Falik‐Borenstein Alexandra Filipovich Yasushi Ishida Sirpa Kivrikko Christoph Klein Friedmar Kreuz Alex Levin Hiroaki Miyajima Jose R. Regueiro Carolyn Russo Eiichiro Uyama Outi Vierimaa Richard A. Spritz 《American journal of medical genetics. Part A》2002,108(1):16-22
Chediak‐Higashi syndrome (CHS) is a rare autosomal recessive disorder characterized by severe immunologic defects, reduced pigmentation, bleeding tendency, and progressive neurological dysfunction. Most patients present in early childhood and die unless treated by bone marrow transplantation. About 10–15% of patients exhibit a much milder clinical phenotype and survive to adulthood, but develop progressive and often fatal neurological dysfunction. Very rare patients exhibit an intermediate adolescent CHS phenotype, presenting with severe infections in early childhood, but a milder course by adolescence, with no accelerated phase. Here, we describe the organization and genomic DNA sequence of the CHS1 gene and mutation analysis of 21 unrelated patients with the childhood, adolescent, and adult forms of CHS. In patients with severe childhood CHS, we found only functionally null mutant CHS1 alleles, whereas in patients with the adolescent and adult forms of CHS we also found missense mutant alleles that likely encode CHS1 polypeptides with partial function. Together, these results suggest an allelic genotype–phenotype relationship among the various clinical forms of CHS. © 2002 Wiley‐Liss, Inc. 相似文献
3.
Nine sawmill workers were divided into two groups according to their exposure to 2-ethylhexanoic acid, (EHA), a pesticide which has replaced the older pentochlorophenol. The men with lower exposure excreted 30±10 nmol EHA/mmol creatinine (mean ±SD,n=4) in urine samples taken after the workshift, whereas men with higher exposure excreted 1.8±1.6 mol EHA/mmol creatinine (mean±SD,n=5,p<0.01). The urinary ornithine and arginine concentrations were at the lower exposure 1.4±0.4 and 1.5±0.8 mol/mmol creatinine, respectively (mean±SD,n=4), and they increased significantly (p<0.01) to 4.5±2.5 and 3.2±1.5mol/mmol (mean±SD,n=5), respectively, at the higher exposure. This might have been caused by the inhibitory effect of EHA on urea synthesis which was partially compensated for by elevated arginine and ornithine concentrations to drive the urea cycle more efficiently. 相似文献
4.
IgE allergen component-based profiling and atopic manifestations in patients with Netherton syndrome
5.
Catarina Paixo Carlos M. Dias Rui Jorge Eliana V. Carraa Mary Yannakoulia Martina de Zwaan Sirpa Soini James O. Hill Pedro J. Teixeira Inês Santos 《Obesity reviews》2020,21(5)
Weight loss maintenance is a major challenge for obesity treatment. Weight control registries can be useful in identifying psychological and behavioural factors that could contribute to better long‐term success. The objective of this study is to describe the existing weight control registries and their participants and identify correlates of weight loss maintenance. A comprehensive search of peer‐reviewed articles published until November 2018 was conducted in PubMed, Web of Science, and Scopus. Studies that reported results from weight control registries were considered. Fifty‐two articles, corresponding to five registries (the United States, Portugal, Germany, Finland, and Greece), were included. Registries differed in inclusion criteria and procedures. Of 51 identified weight loss and maintenance strategies, grouped in 14 domains of the Oxford Food and Activity Behaviors taxonomy, the following were the most frequently reported: having healthy foods available at home, regular breakfast intake, increasing vegetable consumption, decreasing sugary and fatty foods, limiting certain foods, and reducing fat in meals. Increased physical activity was the most consistent positive correlate of weight loss maintenance. To our knowledge, this is the first systematic review of information about successful weight loss maintenance obtained from weight control registries. Key common influential characteristics of success were identified, which can inform future prospective studies and weight management initiatives. 相似文献
6.
Sirpa H. Laitinen 《Journal of plastic surgery and hand surgery》2013,47(4):285-290
AbstractDevelopment of the dental arches and length and weight at birth were studied from 0.2 to 6 years of age in 78 children with Pierre Robin syndrome and 58 with isolated cleft palate. The growth of the maxillary dental arches was similar in both groups before palatal closure. The anterior width of the maxillary arch did not differ between the groups during the six year follow up period, but the depths of the maxillary and mandibular arches were significantly less (< 0.001) in the group with Pierre Robin syndrome compared with those with isolated cleft palates at the age of 3 and 6 years. The mandibular width at the first and second deciduous molars in the group with Pierre Robin syndrome was also significantly smaller (<0.01) than in the other group at the age of 6 years. The weight and length at birth were similar in both groups, and they were slightly lower than among the normal Finnish population. 相似文献
7.
Kristiina Vuolukka Päivi Auvinen Jan-Erik Palmgren Tuuli Voutilainen Sirpa Aaltomaa Vesa Kataja 《Brachytherapy》2019,18(5):583-588
PurposeThe purpose of this study was to evaluate the incidence of late severe (≥Grade 3) urinary toxicity and the long-term efficacy after low-dose-rate brachytherapy (LDR-BT) in patients with localized prostate cancer (PCa).Methods and MaterialsDuring the years 1999–2008, 241 patients with PCa who underwent LDR-BT with I125 and were followed up in Kuopio University Hospital were included to this analysis. The incidence of late severe (Grade 3) urinary toxicity and the long-term efficacy results were analyzed.ResultsAll D'Amico risk groups were represented, as 58.9%, 35.3%, and 5.8% of the patients were classified as low-, intermediate-, and high-risk patients, respectively. With a median followup of 11.4 years after implantation, the incidence of severe urinary toxicity increased throughout the followup period. The risk of Grade 3 urinary toxicity was highest among patients with higher Gleason scores (p = 0.016) and higher initial urine residual volumes (p = 0.017) and the cumulative incidence of severe urinary toxicity was 10.0%. The crude rate for transurethral prostatic resection was 5.8%. The relapse-free survival, the cause-specific survival, and the overall survival were 79.3%, 95.0%, and 66.4%, respectively.ConclusionsThe treatment was well tolerated as 90% of patients avoided any Grade 3 urinary toxicity. LDR-BT for localized PCa achieved high and durable efficacy. These results support the role of LDR-BT monotherapy as one of the valid primary treatment options for low-risk and favorable intermediate-risk patients. 相似文献
8.
Marttila-Ichihara F Turja R Miiluniemi M Karikoski M Maksimow M Niemelä J Martinez-Pomares L Salmi M Jalkanen S 《Blood》2008,112(1):64-72
Macrophage mannose receptor (MR) participates in pathogen recognition, clearance of endogenous serum glycoproteins, and antigen presentation. MR is also present on lymphatic vessels, where its function is unknown. Here we show that migration of lymphocytes from the skin into the draining lymph nodes through the afferent lymphatics is reduced in MR-deficient mice, while the structure of lymphatic vasculature remains normal in these animals. Moreover, in a tumor model the primary tumors grow significantly bigger in MR–/– mice than in the wild-type (WT) controls, whereas the regional lymph node metastases are markedly smaller. Adhesion of both normal lymphocytes and tumor cells to lymphatic vessels is significantly decreased in MR-deficient mice. The ability of macrophages to present tumor antigens is indistinguishable between the 2 genotypes. Thus, MR on lymphatic endothelial cells is involved in leukocyte trafficking and contributes to the metastatic behavior of cancer cells. Blocking of MR may provide a new approach to controlling inflammation and cancer metastasis by targeting the lymphatic vasculature. 相似文献
9.
10.
Martin Dreyling Armando Santoro Luigina Mollica Sirpa Leppä George Follows Georg Lenz Won Seog Kim Arnon Nagler Maria Dimou Judit Demeter Muhit Özcan Marina Kosinova Krimo Bouabdallah Franck Morschhauser Don A. Stevens David Trevarthen Javier Munoz Liana Rodrigues Florian Hiemeyer Ashok Miriyala Jose Garcia-Vargas Barrett H. Childs Pier Luigi Zinzani 《American journal of hematology》2020,95(4):362-371
Safety profiles of oral PI3K inhibitors have resulted in US FDA black box warnings regarding fatal/serious toxicities. The approved intravenous PI3K inhibitor copanlisib has low incidence of severe toxicities and no black box warnings, but chronic treatment effects were unknown. We provide an update on safety and efficacy of copanlisib with a minimum 2-year follow-up of the CHRONOS-1 study. A total of 142 patients with histologically confirmed indolent B-cell lymphoma who had relapsed after or were refractory to ≥2 prior treatments received intravenous copanlisib 60 mg on days 1, 8, and 15 (28-day cycle). The primary efficacy endpoint was objective response rate (ORR) after ≥4 cycles (independent assessment). The predominant histology was follicular lymphoma (n = 104). The ORR was 60.6% (seven additional complete responses since primary analysis). Secondary endpoints of median duration of response, progression-free survival, and overall survival were 14.1 months (median follow-up, 16.1 months), 12.5 months (median follow-up, 14.0 months), and 42.6 months (median follow-up, 31.5 months), respectively. Median safety follow-up was 6.7 months; 26% of patients received treatment for >1 year. Common treatment-emergent adverse events (TEAEs) (all grade/grade 3/grade 4) were transient hyperglycemia (50.0%/33.1%/7.0%), diarrhea (35.2%/8.5%/0%), transient hypertension (29.6%/23.9%/0%), and neutropenia (28.9%/9.2%/14.8%). Serious AEs were largely unchanged, with no new cases of pneumonitis (4.2%), diarrhea (2.8%), or grade 5 events. Note, TEAEs showed no evidence for increased incidence or worsening following longer exposure in patients treated >1 year. Long-term follow-up of patients with relapsed/refractory indolent B-cell lymphoma treated with intravenous copanlisib demonstrated durable, enhanced responses without evidence of worsening TEAEs, as reported for orally administered PI3K inhibitors. 相似文献